Trial Profile

A Phase 2, Four-week, Dose Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ATN-249 as a Preventative Treatment to Reduce the Frequency of Attacks in Hereditary Angioedema (HAE) Patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATN 249 (Primary)
Indications Hereditary angioedema
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Attune Pharmaceuticals

23 Jan 2020 According to an Attune Pharmaceuticals media release, the company announced the completion of a $23 million Series B financing which will rapidly advance ATN-249 through phase 2 program.
29 Jan 2019 New trial record
22 Jan 2019 According to an Attune Pharmaceuticals media release, this study is expected to begin upon conclusion of the phase I study in healthy volunteers.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com